Text Size

Glaucomatous optic neuropathy treatment options: The promise of novel therapeutics, techniques and tools to help preserve vision

Sharif N.

  • 2018
  • Neural Regeneration Research
View publication
  • Therapeutic Area


  • Technology

    Drug Delivery

  • Categories

    Disease understanding (epidemiology, diagnosis, QoL, Biomarkers…)

  • Affiliations

    Department of Global Alliances and External Research, Global Ophthalmology Research and Development, Santen Incorporated, Emeryville, CA, United States; Department of Pharmaceutical Sciences, Texas Southern University, Houston, TX, United States; Department of Pharmacology and Neuroscience, University of North Texas Health Sciences Center, Fort Worth, TX, United States; Department of Pharmacy Sciences, Creighton University, Omaha, NE, United States; Department of Surgery and Cancer, Imperial College of Science and Technology, St. Mary's Campus, London, United Kingdom

Related Publications

IDrugs and idevices discovery research: Preclinical assays, techniques, and animal model studies for ocular hypotensives and neuroprotectants

Sharif N.A.

MicroRNA profile of extracellular vesicles released by Müller glial cells

Lamb W D.B.; Eastlake K.; Luis J.; Sharif N.A. ; Khaw P. T.; Limb G. A.

Steroid-Induced Ocular Hypertension in Mice Is Differentially Reduced by Selective EP2, EP3, EP4, and IP Prostanoid Receptor Agonists

Sharif N.A.; Millar J.C.; Zode G.; Ota T.

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022